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Summary
Background The Patient-Oriented Eczema Measure (POEM) is a validated, patient-
derived assessment measure for monitoring atopic eczema severity, although
further information on how different POEM scores translate into disease severity
categories is needed for clinical trials, epidemiological research and audit.
Objectives We sought to determine the relationship between Patient-Oriented
Eczema Measure (POEM) scores (range 0–28) and two Global Questions (GQ1
and 2) concerning patients’/parents’ views of the overall severity of their/their
child’s atopic eczema, in order to stratify POEM scores into five severity bands.
Methods POEM scores and GQs were completed by 300 patients from general
practice and 700 patients from dermatology outpatient clinics, including 300
adults aged ≥ 16 years and 700 children.
Results The mean POEM score was 136 (range 0–28), and standard deviation
(SD) was 72. Mean GQ1/GQ2 scores were 21/21, respectively (range 0–4 and
SD 11 for both). The mean, mode and median of the GQ scores for each POEM
score were used to devise possible POEM bandings. The proposed banding for
POEM scores are: 0–2 (clear/almost clear); 3–7 (mild); 8–16 (moderate); 17–24
(severe); 25–28 (very severe), kappa coefficient 046.
Conclusions Severity banding of the POEM will allow more clinically meaningful
use in everyday clinical practice and as a core outcome measure in future atopic
eczema research.
What’s already known about this topic?
• The POEM is a validated, reliable and simple tool for measuring atopic eczema
severity in adults and children.
• POEM scores can range from 0 to 28, and have shown longitudinal sensitivity to
change in the outpatient clinic and in clinical trials.
What does this study add?
• Using global patient-assessed anchor questions, POEM scores were categorized into
five severity bands to improve interpretation in clinical practice and research.
POEM scores of 0–2 = clear/almost clear, 3–7 = mild, 8–16 = moderate,
17–24 = severe, and 25–28 = very severe atopic eczema.
Advances in atopic eczema therapy depend on the availability
of validated outcome measures which reflect disease severity
in a way that is relevant to patients.1 The Patient-Oriented
Eczema Measure (POEM) is a simple, valid, repeatable, and
readily understandable tool for monitoring disease severity in
children and adults with atopic eczema, which was originally
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developed to help readdress the imbalance between physician
and patient-based outcome measures in eczema research
(Fig. 1).2–4
The POEM has been widely recommended as an atopic
eczema outcome measure in reviews and national guide-
lines,5–8 being suitable for use in the outpatient clinic, and for
audit, epidemiological studies and clinical trials.9–11 Scoring
sheets are available free on the U.K. Centre for Evidence Based
Dermatology website (http://www.nottingham.ac.uk/scs/
divisions/evidencebaseddermatology/resources/patientoriente
deczemameasure.aspx). Linguistic translations are available on
the Patient-Reported Outcome and Quality of Life Instruments
Database (http://www.proqolid.org).
POEM scores improve as disease severity and quality of life
improves, with one study suggesting a minimal clinically
important difference (MCID) in POEM score of 34.12 How-
ever, further research is needed to provide information on the
clinical meaning of individual scores, both for entry into clini-
cal trials and outcome analysis.
The aim of this study was to explore the relationship
between POEM scores and two global anchor questions con-
cerning patients’ overall assessment of their disease severity, in
order to establish a range of POEM scores corresponding to
five different categories of disease severity.
Patients and methods
This was an open, prospective study of adult and paediatric
patients with atopic eczema defined according to the U.K.
Working Party’s refinement of the Hanifin and Rajka diagnos-
tic criteria, recruited from primary and secondary care.13 The
POEM was used to measure atopic eczema severity against two
© CR Charman, AJ Venn, HC Williams, December 2004. 
Patient-Oriented Eczema Measure (POEM)
(Questionnaire for adults or children) 
Patient details: Date:
Total POEM score: 
(maximum 28)  
Please circle one response for each of the seven questions below. Young children should 
complete the questionnaire with the help of their parents. Please leave blank any questions you 
feel unable to answer. 
1. Over the last week, on how many days has your/your child’s skin been itchy because of the  
eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
2. Over the last week, on how many nights has your/your child’s sleep been disturbed because 
of the eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
3. Over the last week, on how many days has your/your child’s skin been bleeding because of 
the eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
4. Over the last week, on how many days has your/your child’s skin been weeping or oozing 
clear fluid because of the eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
5. Over the last week, on how many days has your/your child’s skin been cracked because of 
the eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
6. Over the last week, on how many days has your/your child’s skin been flaking off because of 
the eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
7. Over the last week, on how many days has your/your child’s skin felt dry or rough because 
of the eczema? 
No days 1–2 days 3–4 days 5–6 days Every day 
Fig 1. Patient-Oriented Eczema Measure
(POEM), questionnaire for use in adults and
children (or parents/carers) with atopic
eczema.
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global anchor questions (GQ1 and GQ2) relating to disease
severity (Fig. 2). GQ1 was used as the primary outcome mea-
sure. Approval for the study was given by the local Research
and Development departments.
It was estimated that 1000 questionnaires would be needed
to categorize accurately the POEM scores into five bands,
based on the normal distribution of POEM scores, and previ-
ous studies used to categorize patient-based scores using this
method.14 In order to include patients from a diverse social
and ethnic background, recruitment was carried out from two
geographically distant U.K. dermatology outpatient depart-
ments (Royal Devon and Exeter Foundation Trust and Not-
tingham University Hospital NHS Trust) and six general
practice surgeries in Devon, covering both urban and rural
locations.
Data processing and statistical analysis
Data were analysed using SPSS version 20 (IBM Corp., New
York, NY, U.S.A). The distribution of each of the score vari-
ables was summarized using means and standard deviations.
Medians and ranges were also computed because of the ordi-
nal nature of these variables, and nonparametric methods were
used to assess associations. For each POEM score the mean,
mode and median GQ scores were used to group the POEM
scores into possible severity strata (see Table 3), and the kappa
(j) coefficient of agreement was calculated for each set of
bands. A subset analysis was carried out on patients whose
GQ1 scores disagreed with that predicted by two or more
bands.
Results
POEM scores and GQs were completed by 300 consecutive
patients from general practice and 700 consecutive patients
from dermatology outpatient clinics. The participants com-
prised 300 adults aged ≥ 16 years and 700 children (487
females and 513 males, median age 67 months, age range
1 month to 65 years, interquartile range 21 months to
17 years). The distribution of POEM and GQ scores are
shown in Table 1, with slightly higher POEM scores seen in
males (median 14 vs. 13, P = 001 for Mann–Whitney
U-test) but no significant gender difference in GQ scores.
POEM and GQ scores were significantly higher in patients
recruited from secondary care (Mann–Whitney P < 0001;
Table 1), and on average were slightly higher in adults than
children. The Spearman rank correlation coefficient showed a
strong and highly statistically significant correlation between
POEM scores and both the GQ1 (r = 078, P < 0001) and
GQ2 scores (r = 077, P < 0001), which was not signifi-
cantly affected by care setting, age or sex. There was a high
correlation between GQ1 and GQ2 scores (Spearman
r = 082, P < 0001).
For each POEM score from 0 to 28, the distribution and the
mean, mode and median of the corresponding GQ1 and GQ2
scores are shown in Table 2, with grey shaded areas illustrat-
ing POEM scores which could potentially have been included
in either of the two adjacent bands. The two bandings with
the highest K values for GQ1 varied only in the positioning of
POEM scores of 25 (Table 3). Banding option 2 showed
almost as high a K value as banding option 1, and also showed
a higher K value for GQ2. Of patients with POEM scores of
25, 53% rated their eczema as causing ‘a very large amount
of bother’. Therefore banding option 2 was chosen as the final
severity banding: POEM scores 0–2 = clear; 3–7 = mild;
8–16 = moderate; 17–24 = severe; 25–28 = very severe.
Figure 3 illustrates the proposed POEM banding in relation-
ship to the mean, mode and median of GQ1 scores.
Subgroup analysis
Overview of POEM scores falling outside proposed
banding
No patients showed a GQ1 score > 2 points outside of that
predicted by the final POEM severity bands. There were 22
patients (22%) whose actual GQ1 score was two points lower
than the final severity banding would have predicted from their
POEM score, although this figure fell to only two patients
(02%) when using the GQ2 score. There were 15 patients
(15%) whose actual GQ1 score was two points higher than the
final severity banding would have predicted, although again this
figure fell to only nine patients (09%) when patients’ GQ2
scores were used as a measure of disease severity.
GQ1.
How bad has your/your child’s eczema been over the last 
week?
a) Clear (no eczema)    
b) Mild        
c) Moderate       
d) Severe  
e) Very severe      
GQ2.
How much bother or trouble has your/your child’s eczema
caused overall during the last week? 
a) none at all      
b) only a little amount    
c) a moderate amount    
d) a large amount     
e) a very large amount 
Fig 2. Global questions, GQ1 and 2
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POEM scores in 0–2 (clear) category
Table 2 illustrates that although 53 of 75 (71%) of patients in
the clear category self-rated their eczema as ‘clear’, a further
18 of 75 (24%) and 4 of 75 (5%) patients rated their eczema
as mild or moderate, respectively. Dryness and itching were
the most common symptoms reported by patients in this
severity band, with no patients reporting symptoms of acute
eczema such as bleeding or weeping. In view of the difficul-
ties in precisely defining eczema as ‘clear’, the term ‘clear or
almost clear’ was used to define this category.
POEM scores of 25
As the two bandings with the highest K values for GQ1 varied
only in the positioning of POEM scores of 25 in either the
severe or very severe category, the individual symptom scores
of these patients were examined, to justify inclusion in the
‘very severe’ banding. All the patients with POEM scores of 25
reported daily itching and sleep loss of ≥ 5 nights a week,
and 93% reported bleeding ≥ 5 days a week.
Discussion
Currently the POEM is recommended as one of the three most
adequately validated and tested outcome measures for atopic
eczema, alongside the SCORAD index and the Eczema Area
and Severity Index (EASI).1,6,15,16 Of these three outcome
measures, the POEM is the only measure which is fully
patient-derived and patient-assessed. All three outcome
measures provide complementary information on disease
severity.1,6,17
The inclusion of two global patient-rated questions provided
a more accurate measure of eczema severity. Self-assessment of
eczema may be limited by personal experience, or influenced
by comparison with families or friends with the condition.
Similarly, the degree of bother caused by the eczema may be
influenced by external factors at home, school or work. The
assessment of ‘bother’ (as in GQ2) has been used successfully in
asthma outcome measure research, and was easily understood
by patients in the development of the POEM.2
Overall < 4% of patients’ POEM scores fell outside the pro-
posed banding by two bands. The anonymous design of this
study did not allow more detailed analysis of factors contrib-
uting to these outlying scores, although it is recognized that
patients with associated ichthyosis may score highly on
domains such as dryness or roughness and flaking without
significant symptoms of eczema. Patients with low POEM
scores but high GQ scores may reflect less familiarity with the
disease, or worries about prognosis or treatment.
In primary care the POEM bands defined by this research
could be used to support the decision to refer to secondary
care (e.g. in children experiencing 1–2 weeks of flares a
month), or to guide primary care physicians in appropriate
prescribing of topical steroid therapy, with POEM scores of
8–16 or ≥ 17 supporting the need for moderately potent or
potent topical steroids, respectively.8 The POEM severity
banding may also provide a useful decision-making tool for
primary care physicians considering topical calcineurin inhibi-
tor therapy for patients with moderate or severe atopic eczema
(POEM scores of ≥ 8).8
Recent atopic eczema research has focused on the develop-
ment of consensus-based sets of core outcome domains for
atopic eczema, for use in controlled trials and clinical record
Table 1 Distribution of POEM and GQ scores overall and by care setting, sex and age
n
POEM GQ1 GQ2
Mean
(SD)
Median
(IQR) P-valuea
Mean
(SD)
Median
(IQR) P-valuea
Mean
(SD)
Median
(IQR) P -valuea
All patients 1000 1360
(717)
13
(8–19)
210
(106)
2
(1–3)
209
(106)
2
(1–3)
Care setting
Primary 300 885
(527)
9
(425–13) < 0001
157
(094)
2
(1–2) < 0001
159
(096)
2
(1–2) < 0001
Secondary 700 1563
(691)
16
(10–21)
232
(102)
2
(2–3)
231
(103)
2
(2–3)
Sex
Male 513 1418
(744)
14
(8–20) 001
214
(104)
2
(1–3) 030
215
(110)
2
(1–3) 014
Female 487 1298
(683)
13
(8–18)
205
(107)
2
(1–3)
204
(102)
2
(1–3)
Age
Child < 16 700 1333
(739)
13
(8–19) 006
203 (109) 2
(1–3) 001
204
(109)
2
(1–3) 003
Adult 300 1421
(658)
14
(10–19)
224
(096)
2
(2–3)
222
(097)
2
(2–3)
IQR, interquartile range. aP-values computed using Mann–Whitney U-test.
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Table 2 Number of patients with each POEM score and corresponding (a) GQ1 scores and (b) GQ2 scores (global patient-rated disease severity 0
–4)
POEM
score
Patient
total
GQ scores
Proposed
banding0 1 2 3 4 Mean Median Mode
(a)
0 16 16 000 0 0 Clear
1 22 16 6 027 0 0
2 37 21 12 4 054 0 0
3 26 6 20 077 1 1 Mild
4 19 19 100 1 1
5 20 3 10 7 12 1 1
6 56 2 43 11 116 1 1
7 25 12 10 3 164 2 1
8 54 8 13 29 4 154 2 2 Moderate
9 44 7 29 8 202 2 2
10 45 4 6 31 4 178 2 2
11 42 15 16 7 4 200 2 2
12 40 12 24 4 180 2 2
13 55 12 31 10 2 204 2 2
14 36 1 30 5 211 2 2
15 47 4 27 14 2 230 2 2
16 47 27 20 243 2 2
17 47 17 26 4 274 3 3 Severe
18 45 5 20 20 233 2 2/3
19 47 1 21 19 6 264 3 2
20 44 3 12 20 9 280 3 3
21 21 4 14 3 295 3 3
22 40 6 27 7 302 3 3
23 33 2 28 3 303 3 3
24 21 15 6 329 3 3
25 30 1 17 12 337 3 3
26 8 8 400 4 4 Very severe
27 10 7 3 330 3 3
28 23 7 16 370 4 4
(b)
0 16 16 0 0 0
1 22 16 6 027 0 0 Clear
2 37 12 19 6 084 1 1
3 26 13 8 5 069 05 0
4 19 2 17 089 1 1 Mild
5 20 1 7 135 1 1
6 56 7 34 15 114 1 1
7 25 14 9 2 152 1 1
8 54 28 26 148 1 1
9 44 7 31 6 198 2 2 Moderate
10 45 13 28 4 180 2 2
11 42 9 32 1 181 2 2
12 40 5 21 14 210 2 2
13 55 6 35 12 2 218 2 2
14 36 5 28 3 194 2 2
15 47 8 27 10 2 213 2 2
16 47 1 8 18 20 221 2 3
17 47 1 2 13 27 4 266 3 3
18 45 9 19 10 7 236 2 2
19 47 21 16 10 277 3 2 Severe
20 44 17 16 11 286 3 2
21 21 6 15 271 3 3
22 40 8 24 8 300 3 3
23 33 33 300 3 3
24 21 13 8 338 3 3
25 30 14 16 353 4 4
26 8 5 3 338 3 3
27 10 10 4 4 4 Very severe
28 23 8 15 365 4 4
Grey shaded scores represent two possible bandings based on mean, median and mode values and POEM subscore analysis.
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keeping.1 The Harmonizing Outcomes Measures for Eczema
(HOME) initiative has identified four core outcomes which
are recommended for inclusion in all future atopic eczema
trials in order to enhance clinical interpretability and to enable
meta-analyses across different studies: patient symptoms,
physician-assessed clinical signs, quality of life, and a mea-
surement for long-term control of flares.1 The POEM stratifica-
tion proposed in this study offers researchers a tool with
which to capture longitudinal patient symptoms, and long-
term control of flares, with POEM scores of ≥ 8 and ≥ 16
representing moderate to severe flares, respectively, and POEM
scores of ≤ 2 representing eczema in remission. It is hoped
that the POEM will be considered as a core outcome measure
for future atopic eczema clinical trials, with the final severity
bands providing an accurate and easily interpretable patient-
based quantitative measure of long-term disease control.
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